BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19179977)

  • 21. Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.
    Mehdipour P; Pirouzpanah S; Sarafnejad A; Atri M; Shahrestani ST; Haidari M
    Cell Biol Int; 2009 Oct; 33(10):1050-6. PubMed ID: 19555767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.
    Kühling H; Alm P; Olsson H; Fernö M; Baldetorp B; Parwaresch R; Rudolph P
    J Pathol; 2003 Apr; 199(4):424-31. PubMed ID: 12635132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer.
    Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
    J Surg Oncol; 2003 Aug; 83(4):241-7. PubMed ID: 12884237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
    Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
    Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer.
    Koliadi A; Nilsson C; Holmqvist M; Holmberg L; de La Torre M; Wärnberg F; Fjällskog ML
    Acta Oncol; 2010 Aug; 49(6):816-20. PubMed ID: 20307242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
    Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer.
    Kim HK; Park IA; Heo DS; Noh DY; Choe KJ; Bang YJ; Kim NK
    Eur J Surg Oncol; 2001 Aug; 27(5):464-71. PubMed ID: 11504517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.
    Waltersson MA; Askmalm MS; Nordenskjöld B; Fornander T; Skoog L; Stål O
    Int J Oncol; 2009 Feb; 34(2):441-8. PubMed ID: 19148479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.
    Farley J; Smith LM; Darcy KM; Sobel E; O'Connor D; Henderson B; Morrison LE; Birrer MJ;
    Cancer Res; 2003 Mar; 63(6):1235-41. PubMed ID: 12649182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer.
    Bani-Hani KE; Almasri NM; Khader YS; Sheyab FM; Karam HN
    Clin Cancer Res; 2005 Feb; 11(4):1447-53. PubMed ID: 15746045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay.
    Potemski P; Pluciennik E; Bednarek AK; Kusinska R; Kubiak R; Jesionek-Kupnicka D; Watala C; Kordek R
    Pathol Res Pract; 2006; 202(7):491-5. PubMed ID: 16678980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
    Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
    Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
    Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression.
    Choi MG; Noh JH; An JY; Hong SK; Park SB; Baik YH; Kim KM; Sohn TS; Kim S
    J Surg Res; 2009 Dec; 157(2):168-74. PubMed ID: 19559447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
    Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
    Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients.
    Farmen RK; Nordgård O; Gilje B; Shammas FV; Kvaløy JT; Oltedal S; Heikkilä R
    Breast Cancer Res Treat; 2008 Mar; 108(2):251-8. PubMed ID: 17492378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
    Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
    Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.